Published in Scand J Immunol on May 01, 1999
C-Kit receptor (CD117) in the porcine urinary tract. Pediatr Surg Int (2008) 1.00
Human endothelial cells regulate survival and proliferation of human mast cells. J Exp Med (2000) 0.97
Role of keratinocytes in the development of vitiligo. Ann Dermatol (2012) 0.89
Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. Br J Cancer (2000) 0.83
Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells. Immunology (2000) 0.80
Skipping of exons by premature termination of transcription and alternative splicing within intron-5 of the sheep SCF gene: a novel splice variant. PLoS One (2012) 0.77
Association of stem cell factor gene expression with severity and atopic state in patients with bronchial asthma. Respir Res (2017) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy (1998) 3.20
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy (2004) 2.13
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy (2008) 1.66
Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol (2014) 1.60
Insulin allergy: clinical manifestations and management strategies. Allergy (2008) 1.56
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Mast cells. Int J Dermatol (1995) 1.52
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49
Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production. Clin Exp Allergy (2009) 1.47
Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy (2004) 1.45
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44
HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart (2009) 1.42
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy (2007) 1.16
Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13
Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08
Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06
Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol (2008) 1.06
ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy (2008) 1.05
Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03
GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03
Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02
Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02
Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01
Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence. Allergy (2009) 0.99
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy (2009) 0.99
Personalized pollen-related symptom-forecast information services for allergic rhinitis patients in Europe. Allergy (2013) 0.98
Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy (2008) 0.97
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97
Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods (1988) 0.97
Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97
Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97
Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy (2007) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy (2011) 0.95
Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. J Invest Dermatol (1984) 0.95
The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA(2)LEN review. Allergy (2008) 0.95
Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3. Rhinology (2006) 0.95
Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95
The relation between paracetamol use and asthma: a GA2LEN European case-control study. Eur Respir J (2008) 0.94
Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94
Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94
Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93
Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes. Agents Actions Suppl (1983) 0.93
Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy (2012) 0.93
Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93
Hepatitis C virus infection rate in volunteer blood donors from the Western Cape--comparison of screening tests and PCR. S Afr Med J (1997) 0.92
A combination of wheat flour, ethanol and food additives inducing FDEIA. Allergy (2002) 0.92
Chemotactic leukotrienes in psoriasis. Lancet (1982) 0.92
Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92
Bifunctional thrombin inhibitors based on the sequence of hirudin45-65. J Biol Chem (1990) 0.91
Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy (2008) 0.91
Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91
Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91
Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91
Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. Nat Genet (1996) 0.91
Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90